RNA结合蛋白人源抗原R（HuR）是转录后水平基因表达的一个被广泛接受的调节因子。HuR的失调与多种人类疾病，尤其是癌症相关。在癌症中，当HuR显示增强的细胞质定位时，它被认为是“活跃的”，除了其正常的核定位。细胞质中的HuR在稳定和促进与癌症进展相关的应激反应中所涉及的促生存mRNA的翻译中起着至关重要的作用。与正常细胞相比，癌细胞中HuR的丰度和活性使其成为抗癌治疗的有吸引力的靶标。本综述旨在探讨HuR在稳态和癌症病理生理学中的作用，以及目前的靶向策略。此外，我们讨论了近期研究中对HuR抑制和传统化疗药物潜在协同作用的探索，这些研究支持利用HuR在肿瘤发生和对应激反应的耐药中所扮演的功能原理增强其他疗法的疗效的潜力。

The RNA-binding protein human antigen R (HuR) is a well-established regulator of gene expression at the post-transcriptional level. HuR dysregulation has been implicated in various human diseases, particularly cancer. HuR is considered "active" in cancer when it shows increased subcellular localization in the cytoplasm, in addition to its normal nuclear localization. Cytoplasmic HuR plays a crucial role in stabilizing and enhancing the translation of pro-survival mRNAs that are involved in stress responses relevant to cancer progression. The abundance and activity of HuR in cancer cells compared to normal cells makes it an appealing target for cancer treatment. This review aims to explore the role of HuR in homeostasis and cancer pathophysiology, as well as current targeting strategies. Furthermore, we discuss recent studies investigating potential synergy between HuR inhibition and traditional chemotherapeutics, which support the potential of exploiting the principles underlying the function of HuR in tumorigenesis and resistance to stressors to enhance the efficacy of other therapies.